NCT07190755 Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cell Carcinoma (HNSCC)
| NCT ID | NCT07190755 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Henri Becquerel |
| Condition | Head and Neck Squamous Cell Carcinoma HNSCC |
| Study Type | INTERVENTIONAL |
| Enrollment | 192 participants |
| Start Date | 2025-10-15 |
| Primary Completion | 2030-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 192 participants in total. It began in 2025-10-15 with a primary completion date of 2030-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The use of digital strategies to systematically monitor patients' symptoms in clinical settings allows problems to be detected at an early stage before they worsen or lead to complications. In this study, the hypothesis is that the proportion of patients with a weight loss of at least 5% between before radiotherapy/radiochemotherapy and 3 months after treatment would be lower with optimised care thanks to remote monitoring using a medical telemonitoring solution in oncology.
Eligibility Criteria
Inclusion Criteria: * Patient aged over 18 and under 75 years WHO score \< 2, * Treated for localised heand and neck cancer of the squamous cell carcinoma type for which curative treatment has been chosen and receiving radiotherapy or radio-chemotherapy exclusively or as an adjuvant with the aim of cure * Having signed the informed consent form, * Affiliated with or beneficiary of a social protection scheme, * Access to a smartphone or the internet, Exclusion Criteria: * History of other neoplastic disease less than 2 years ago or progressive disease, * History of ENT radiotherapy, * Pregnant or breastfeeding women, * Protected adults (under guardianship, curatorship or judicial protection), * Patients participating in a therapeutic study, * Patients unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological or geographical issues, etc.), patients with blindness preventing the use of the medical telemonitoring solution in oncology.
Contact & Investigator
Sebastien Thureau, MD,PhD
PRINCIPAL INVESTIGATOR
Centre Henri Becquerel
Frequently Asked Questions
Who can join the NCT07190755 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Head and Neck Squamous Cell Carcinoma HNSCC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07190755 currently recruiting?
Yes, NCT07190755 is actively recruiting participants. Contact the research team at sebastien.thureau@chb.unicancer.fr for enrollment information.
Where is the NCT07190755 trial being conducted?
This trial is being conducted at Rouen, France, Vandœuvre-lès-Nancy, France.
Who is sponsoring the NCT07190755 clinical trial?
NCT07190755 is sponsored by Centre Henri Becquerel. The principal investigator is Sebastien Thureau, MD,PhD at Centre Henri Becquerel. The trial plans to enroll 192 participants.